GAVI SUPPORT FOR ACCESS TO APPROPRIATE PRICING (ATAP) FOR GAVI GRADUATED COUNTRIES

BOARD MEETING
Wilson Mok, Aurelia Nguyen
10-11 June 2015, Geneva

Reach every child
www.gavi.org
Objective of access to appropriate pricing work

Objective: Support access to appropriate pricing so that countries can sustain immunisation programmes begun with Gavi support and continue to introduce high-quality, life-saving vaccines

In seeking to achieve this objective, we assume that:

- Appropriate price is a necessary aspect to sustain immunisation programmes, although not only aspect
- ‘Appropriate price’ defined as ‘as close to the Gavi price as possible’ to avoid further rapid budget increase and improve countries’ ability-to-pay
- Solution should focus on countries entering Phase 3 in the next five to ten years, but provide a platform for longer-term
Effective solution requires appropriate price and ability to access that price

An effective solution must achieve ...

1. APPROPRIATE PRICE
   - Manufacturer commitments helpful but gaps and limitations
   - Some vaccines not covered, including most introductions with country financing
   - Rotavirus and HPV particularly affected

2. ABILITY TO ACCESS THAT APPROPRIATE PRICE
   - Most countries face challenges, with partners supporting to resolve
   - Could pose barriers to accessing commitments through UNICEF SD
   - Some countries may have challenges to utilising UNICEF SD due to legislation
   - Self-procurement capacity often limited

Gap analysis explored specific areas

- VACCINE PRICING
  - Manufacturer price commitments and market competition

- PAYMENT EFFICIENCY CHALLENGES

- PROCUREMENT EFFICIENCY CHALLENGES
## Proposed solution to address gaps

<table>
<thead>
<tr>
<th>Gap</th>
<th>Phase 3</th>
<th>Beyond Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>VACCINE PRICING</td>
<td><strong>Ongoing market shaping and price transparency initiatives</strong></td>
<td>Countries utilise own procurement and payment mechanisms or those available for MICs (some developed through MIC Strategy)</td>
</tr>
<tr>
<td><strong>Tendering mechanism:</strong></td>
<td><strong>Fully self-financing Gavi countries can choose to participate in UNICEF/Gavi tenders with aim of accessing Gavi prices; operationalises and addresses gaps in commitments</strong></td>
<td></td>
</tr>
<tr>
<td>PAYMENT EFFICIENCY CHALLENGES</td>
<td><strong>Payment mechanism:</strong> If needed, countries utilise UNICEF VII, a revolving fund that provides short-term credit to help with pre-payment; internal processes strengthened in parallel.</td>
<td></td>
</tr>
<tr>
<td>PROCUREMENT EFFICIENCY CHALLENGES</td>
<td><strong>As needed, support during Phase 2 continues to be implemented by partners, coordinated through MIC Strategy</strong></td>
<td></td>
</tr>
</tbody>
</table>

Solution available for 5 years for each Phase 3 country choosing to participate
Collaborative engagement with PAHO helps enable proposal

- PAHO Revolving Fund has driven unprecedented gains in immunisation in the Americas
- PAHO has provided exceptions to lowest price clause for certain vaccines
- Gavi and PAHO developed collaborative solution whereby fully self-financing Gavi countries can participate in UNICEF/Gavi tenders under current exceptions
- Agreement provides foundation to work collectively towards increased access to vaccines and sustainability of immunisation programmes for countries
# Risks and Mitigation

<table>
<thead>
<tr>
<th>RISKS</th>
<th>IMPLICATIONS AND MITIGATION STRATEGIES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TENDER PRICING</strong></td>
<td>- Large, secure demand base, combined with low Phase 3 country volume, limits risk of higher prices</td>
</tr>
<tr>
<td>Higher prices from manufacturers and negative impact on non-Gavi MICs</td>
<td>- Support for robust demand forecasts to achieve best pricing</td>
</tr>
<tr>
<td></td>
<td>- Flexibility and manufacturer engagement to optimise outcomes</td>
</tr>
<tr>
<td></td>
<td>- Minimal impact on non-Gavi MICs given low Phase 3 volumes</td>
</tr>
<tr>
<td><strong>COUNTRY OWNERSHIP</strong></td>
<td>- Solution preserves country choice and full ownership of financing</td>
</tr>
<tr>
<td>Perverse incentives for countries</td>
<td>- Countries meet key terms to participate</td>
</tr>
<tr>
<td><strong>INCOMPLETE SOLUTION</strong></td>
<td>- Partners support countries in capacity building</td>
</tr>
<tr>
<td>Limited impact without addressing non-price issues</td>
<td>- Important that sufficient resources are available for complementary initiatives (MIC Strategy)</td>
</tr>
</tbody>
</table>
Recommendation

The Gavi Board is recommended to:

Approve the Alliance’s approach to ensuring access to appropriate pricing for Phase 3 [graduated] Gavi countries by:

1. Continuing to seek appropriate and sustainable prices through market shaping activities consistent with Gavi’s Vaccine Supply and Procurement Strategy.

2. Allowing Phase 3 [graduated] Gavi countries to be included in UNICEF tenders on behalf of Gavi-eligible and Phase 2 [graduating] countries for specific vaccines with the aim of continuing to provide them with access to Gavi prices for a five year period (provided a country commits to key terms to be defined by UNICEF and Gavi).

3. Providing a catalytic investment of US$ 5 million towards the capitalisation of UNICEF’s Vaccine Independence Initiative (VII), a revolving fund which supports timely availability of financing for countries to meet payment terms. The use of this investment will be prioritised towards Gavi countries, subject to UNICEF approval of each country application to participate in VII. In 2017, the PPC will review the performance of the investment to determine whether there is a need to adjust the amount.
THANK YOU

Reach every child
www.gavi.org